EUCTR2015-001218-92-Outside-EU/EEA进行中（未招募）不适用
A prospective, open-labeled, multicenter study of optimal dosages of OROS-methylphenidate in treating children and adolescents with Attention-Deficit Hyperactivity Disorder
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 145
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Guardian has provided a written consent for subject
- •- Male and female patients from 6 to 18 years of age
- •- Subject diagnosed with ADHD by K-SADS-PL(Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version- Korean Version), and it is determined that he/she requires drug therapy
- •- Able to observe the study’s visit schedule, and the subject and his/her parent/guardians are willing and able to complete the evaluation defined in the Clinical Protocol during the treatment period
- •- Subject/guardian who can understand the participation in the study and spontaneously request discontinuation of the study anytime
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 145
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Subject who was administered with Methylphenidate HCl besides Concerta® within 24 hrs of study participation
- •- Subject who was administered with Concerta within the recent three months
- •- Subject who is known to have hypersensitivity to Methylphenidate HCI or other ingredient of this product
- •- Subject who was administered with the following medications within the last 4 weeks: clonidine or alpha-2 adrenergic receptor agonist, anti-depressants like TCAs or SSRIs (except for Fluoxetine, a subject administered with the drug within 12 weeks is included in the exclusion criteria.), theophylline, coumarin or anticonvulsants, anti-psychotics, benzodiazepines, modafinil
- •- Subject with clinically significant GI problem with a possibility of GI tract obstruction including GI tract stenosis (by pathological or doctor’s diagnosis). For example, intestinal inflammation, short gut syndrome due to adhesion or decrease of transit time, previous history of peritonitis, cystic fibrosis, chronic intestinal pseudo-obstruction or Meckel’s diverticulum
- •- Subject with glaucoma, current seizure disorders like epilepsy, mental disease, Tourette’s syndrome, cardiovascular disease including moderate to severe hypertension, excessive agitation or restlessness, or hyperthyroidism
- •- Subject with other accompanying disease that could inhibit the safe administration of methylphenidate, or subject who is administered with such concomitant drugs
- •- Subject unable to swallow the investigational product
- •- When drug abuse is currently known or suspected, or subject has a history of drug abuse
- •- Subject with mental retardation (IQ of less than 70)
- •- Subject with high risk of pregnancy
- •- Subject either started or changed to a new behavioral therapy for ADHD during the study period
- •- Subject with overall developmental disorder
- •- Subject who is taking oriental herbal medicines
研究者
相似试验
已完成
4 期
OsteoArthritis Synvisc-One (Hylan G-F 20) Indian Post Marketing Study (OASIS)CTRI/2010/091/000052Genzyme India Pvt. Ltd.400
进行中（未招募）
不适用
A prospective, multi-centre, open-label study to establish the equipotent dose ratio after switching from strong opioids to Transtec® in subjects with pain due to cancer - Transtec® in Cancer paicancer painEUCTR2004-004624-13-GBBarts and The London NHS Trust180
进行中（未招募）
1 期
A clinical trial to compare the occurrence (or incidence) of the most common fair skin cancer in solid organ transplant recipients (squamous cell carcinoma) and its preliminary stage (actinic keratoses) in two different groups: One group is treated with a fixed combination of a cream followed by exposure to red light and the other group receives liquid nitrogen (cryotherapy) as lesion-directed therapy.Squamous Cell Carcinoma and Actinic Keratoses in solid organ transplant recipientsMedDRA version: 14.1Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-004111-32-DECharité Universitätsmedizin Berlin70
招募中
3 期
An open-label, single-arm, multicenter study of intracerebral administration of adeno-associated viral vectors serotype rh.10 carrying the human N-sulfoglycosamine sulfohydrolase (SGSH) cDNA for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA)MPS IIISanfilippo syndrome1002742410057167NL-OMON52445ysogene SA10
已完成
3 期
Clinical study to assess the safety and Efficacy of Adult live Cultured cells (Osteoblasts) in subjects with Avascular Necrosis.CTRI/2015/04/005662Regenerative Medical Services Pvt Ltd12